A potential Chinese vaccine to treat novel coronavirus has shown promise in animals trials, triggering an immune system, a peer-reviewed study found.&nbsp;

ARCoV is developed using technology similar to other COVID-19 vaccine candidates: Moderna and BioNtech and Pfizer.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/chinas-sinopharm-says-coronavirus-vaccine-could-be-ready-by-year-end-315363">China's Sinopharm says coronavirus vaccine could be ready by year-end</a>

The trials in monkeys and mice, published in the medical journal Cell on Thursday, found both single and two-dose inoculations triggered strong antibody and T-cell responses against many COVID-19-causing virus strains.

Also read |&nbsp;<a href="https://www.wionews.com/world/first-use-of-coronavirus-vaccines-cannot-be-expected-until-early-2021-who-expert-315293">First use of coronavirus vaccines cannot be expected until early 2021: WHO expert</a>

However, the study couldn't find for how long the antibodies last or how effective their protection might be to other strains that cause coronavirus but were not tested in the study.

Researchers also said the drug is stable at 25°C (77°F) for at least a week, implying it could be easily ciruclated in hard-to-reach regions where cold-chain storage and transporation remain an issue.&nbsp;

Presently, there are over 150 potential COVID-19 vaccines that are in the race to treat novel coronavirus that has killled more than 600,000 people across the world.&nbsp;

A potential Chinese vaccine to treat novel coronavirus has shown promise in animals trials, triggering an immune system, a peer-reviewed study found. ARCoV is developed using technology similar to other COVID-19 vaccine candidates: Moderna and BioNtech and Pfizer.

A potential Chinese vaccine to treat novel coronavirus has shown promise in animals trials, triggering an immune system, a peer-reviewed study found. ARCoV is developed using technology similar to other COVID-19 vaccine candidates: Moderna and BioNtech and Pfizer. Also read | China's Sinopharm says coronavirus vaccine could be ready by year-end The trials in monkeys and mice, published in the medical journal Cell on Thursday, found both single and two-dose inoculations triggered strong antibody and T-cell responses against many COVID-19-causing virus strains. Also read | First use of coronavirus vaccines cannot be expected until early 2021: WHO expert However, the study couldn't find for how long the antibodies last or how effective their protection might be to other strains that cause coronavirus but were not tested in the study. Researchers also said the drug is stable at 25°C (77°F) for at least a week, implying it could be easily ciruclated in hard-to-reach regions where cold-chain storage and transporation remain an issue. Presently, there are over 150 potential COVID-19 vaccines that are in the race to treat novel coronavirus that has killled more than 600,000 people across the world.

Coronavirus vaccine: Chinese candidate shows promise in animal trials

The first shipment of a potential COVID-19 vaccine being developed by China has now landed in Brazil. Sao Paulo has received 20,000 doses of CoronaVac which is being developed with a Chinese frim Sinovac. Watch report.

Why is China conducting Phase-3 trials in other countries: China's vaccine test to start in Brazil

Coronavirus pandemic: Brazil to start clinical trials of Chinese vaccine candidate